Research programme: tubulin polymerisation inhibitors - Ipsen
Alternative Names: IRC-083927; STX 140; STX 243; STX 2484; Tetrahydroisoquinoline-based compounds; THIQ-based compoundsLatest Information Update: 04 Nov 2017
At a glance
- Originator Sterix
- Developer Ipsen
- Class Antineoplastics; Cyclopentanes; Phenanthrenes
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Microtubule protein inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (PO)
- 16 Nov 2010 Preclinical development is ongoing in the UK - compound optimisation update presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
- 09 Sep 2010 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours presented at the 21st International Symposium on Medicinal Chemistry (ISMC-2010)